Possible role of LCZ696 in atherosclerosis: new inroads and perspective.

Nalivaeva NN, Zhuravin IA, Turner AJ (2020) Neprilysin expression and functions in development, ageing and disease. Mech Ageing Dev 1(192):111363

doi: 10.1016/j.mad.2020.111363

Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D (2019) Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc 8(13):e012272

pubmed: 31240976 pmcid: 6662364 doi: 10.1161/JAHA.119.012272

Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609–1620

pubmed: 31475794 doi: 10.1056/NEJMoa1908655

Pardossi-Piquard R, Dunys J, Yu G, StGeorge-Hyslop P, Alves da Costa C, Checler F (2006) Neprilysin activity and expression are controlled by nicastrin. J Neurochem 97(4):1052–6

pubmed: 16606360 doi: 10.1111/j.1471-4159.2006.03822.x

Bayes-Genis A, Prickett TC, Richards AM, Barallat J, Lupón J (2016) Soluble neprilysin retains catalytic activity in heart failure. J Heart Lung Transplant 35(5):684–685

pubmed: 26830756 doi: 10.1016/j.healun.2015.12.015

Bayés-Genís A, Barallat J, Galán A, De Antonio M, Domingo M, Zamora E, Urrutia A, Lupón J (2015) Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol 65(7):657–665

pubmed: 25677426 doi: 10.1016/j.jacc.2014.11.048

Goliasch G, Pavo N, Zotter-Tufaro C, Kammerlander A, Duca F, Mascherbauer J, Bonderman D (2016) Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail 18(1):89–93

pubmed: 26725876 doi: 10.1002/ejhf.435

Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Januzzi JL, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D (2015) Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC 3(8):629–36

pubmed: 26251090

Mishra D, Singh S, Narayan G (2016) Role of B cell development marker CD10 in cancer progression and prognosis. Mol Biol Int. https://doi.org/10.1155/2016/4328697

doi: 10.1155/2016/4328697 pubmed: 27965895 pmcid: 5124668

Reynaud D, Lefort N, Manie E, Coulombel L, Levy Y (2003) In vitro identification of human pro-B cells that give rise to macrophages, natural killer cells, and T cells. Blood 101(11):4313–4321

pubmed: 12560235 doi: 10.1182/blood-2002-07-2085

Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A, Wen W, Liu WM, Kahl BS, d’Amore ES, Montes-Moreno S (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26(9):2103–2113

pubmed: 22437443 pmcid: 3637886 doi: 10.1038/leu.2012.83

Revuelta-López E, Núñez J, Gastelurrutia P, Cediel G, Januzzi JL, Ibrahim NE, Emdin M, VanKimmenade R, Pascual-Figal D, Núñez E, Gommans F (2020) Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Fail 7(2):559–566

pubmed: 32045114 pmcid: 7160502 doi: 10.1002/ehf2.12607

Libby P (2021) The changing landscape of atherosclerosis. Nature 592(7855):524–533

pubmed: 33883728 doi: 10.1038/s41586-021-03392-8

Fok PW, Lanzer P (2018) Media sclerosis drives and localizes atherosclerosis in peripheral arteries. PLoS One 13(10):e0205599

pubmed: 30365531 pmcid: 6203409 doi: 10.1371/journal.pone.0205599

Roh JW, Kwon BJ, Ihm SH, Lim S, Park CS, Chang K, Chung WS, Kim DB, Kim SR, Kim HY (2019) Predictors of significant coronary artery disease in patients with cerebral artery atherosclerosis. Cerebrovasc Dis 48(3–6):226–235

pubmed: 31825937 doi: 10.1159/000504927

Lovshin JA, Bjornstad P, Lovblom LE, Bai JW, Lytvyn Y, Boulet G, Farooqi MA, Santiago S, Orszag A, Scarr D, Weisman A (2018) Atherosclerosis and microvascular complications: results from the canadian study of longevity in type 1 diabetes. Diabetes Care 41(12):2570–2578

pubmed: 30275283 pmcid: 6245210 doi: 10.2337/dc18-1236

Schipper HS, de Ferranti S (2022) Atherosclerotic cardiovascular risk as an emerging priority in pediatrics. Pediatrics. https://doi.org/10.1542/peds.2022-057956

doi: 10.1542/peds.2022-057956 pubmed: 36321395

Vergallo R, Crea F (2020) Atherosclerotic plaque healing. N Engl J Med 383(9):846–857

pubmed: 32846063 doi: 10.1056/NEJMra2000317

Shi P, Ji H, Zhang H, Yang J, Guo R, Wang J (2020) circANRIL reduces vascular endothelial injury, oxidative stress and inflammation in rats with coronary atherosclerosis. Exp Ther Med 20(3):2245–2251

pubmed: 32765701 pmcid: 7401493

Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M (2019) The effects of oxidative stress on the development of atherosclerosis. Biol Chem 400(6):711–732

pubmed: 30864421 doi: 10.1515/hsz-2018-0397

Oliveira HC, Vercesi AE (2020) Mitochondrial bioenergetics and redox dysfunctions in hypercholesterolemia and atherosclerosis. Mol Aspects Med 1(71):100840

doi: 10.1016/j.mam.2019.100840

Hartley A, Haskard D, Khamis R (2019) Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis–Novel insights and future directions in diagnosis and therapy. Trends Cardiovasc Med 29(1):22–26

pubmed: 29934015 doi: 10.1016/j.tcm.2018.05.010

Khatana C, Saini NK, Chakrabarti S, Saini V, Sharma A, Saini RV, Saini AK (2020) Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis. Oxid Med Cell Longev 15:2020

Jinnouchi H, Sato Y, Sakamoto A, Cornelissen A, Mori M, Kawakami R, Gadhoke NV, Kolodgie FD, Virmani R, Finn AV (2020) Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability. Atherosclerosis 1(306):85–95

doi: 10.1016/j.atherosclerosis.2020.05.017

Ito F, Ito T (2020) High-density lipoprotein (Hdl) triglyceride and oxidized HDL: new lipid biomarkers of lipoprotein-related atherosclerotic cardiovascular disease. Antioxidants 9(5):362

pubmed: 32357465 pmcid: 7278571 doi: 10.3390/antiox9050362

Gill PK, Dron JS, Hegele RA (2021) Genetics of hypertriglyceridemia and atherosclerosis. Curr Opin Cardiol 36(3):264–271

pubmed: 33818545 doi: 10.1097/HCO.0000000000000839

Hegele RA, Borén J, Ginsberg HN, Arca M, Averna M, Binder CJ, Calabresi L, Chapman MJ, Cuchel M, von Eckardstein A, Frikke-Schmidt R (2020) Rare dyslipidaemias, from phenotype to genotype to management: a European atherosclerosis society task force consensus statement. Lancet Diabetes Endocrinol 8(1):50–67

pubmed: 31582260 doi: 10.1016/S2213-8587(19)30264-5

Jinnouchi H, Guo L, Sakamoto A, Torii S, Sato Y, Cornelissen A, Kuntz S, Paek KH, Fernandez R, Fuller D, Gadhoke N (2020) Diversity of macrophage phenotypes and responses in atherosclerosis. Cell Mol Life Sci 77(10):1919–1932

pubmed: 31720740 doi: 10.1007/s00018-019-03371-3

Poznyak AV, Grechko AV, Orekhova VA, Chegodaev YS, Wu WK, Orekhov AN (2020) Oxidative stress and antioxidants in atherosclerosis development and treatment. Biology 9(3):60

pubmed: 32245238 pmcid: 7150948 doi: 10.3390/biology9030060

Ho F, Watson A, Elbatreek MH, Kleikers PW, Khan W, Sourris KC, Dai A, Jha J, Schmidt HH, Jandeleit-Dahm KA (2022) Endothelial reactive oxygen-forming NADPH oxidase 5 is a possible player in diabetic aortic aneurysm but not atherosclerosis. Sci Rep 12(1):1

doi: 10.1038/s41598-022-15706-5

Pejenaute Á, Cortés A, Marqués J, Montero L, Beloqui Ó, Fortuño A, Martí A, Orbe J, Zalba G (2020) NADPH oxidase overactivity underlies telomere shortening in human atherosclerosis. Int J Mol Sci 21(4):1434

pubmed: 32093292 pmcid: 7073034 doi: 10.3390/ijms21041434

Ye Z, Guo H, Wang L, Li Y, Xu M, Zhao X, Song X, Chen Z, Huang R (2022) GALNT4 primes monocytes adhesion and transmigration by regulating O-Glycosylation of PSGL-1 in atherosclerosis. J Mol Cell Cardiol 1(165):54–63

doi: 10.1016/j.yjmcc.2021.12.012

Wang C, Wang H, Zhao Z, Xiao S, Zhao Y, Duan C, Gao L, Li S, Wang J (2019) Pediococcus acidilactici AS185 attenuates early atherosclerosis development through inhibition of lipid regulation and inflammation in rats. J Funct Foods 1(60):103424

doi: 10.1016/j.jff.2019.103424

He D, Zhao M, Wu C, Zhang W, Niu C, Yu B, Jin J, Ji L, Willard B, Mathew AV, Chen YE (2018) Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1. Redox Biol 1(15):228–242

doi: 10.1016/j.redox.2017.11.027

Zhang H, Liu G, Zhou W, Zhang W, Wang K, Zhang J (2019) Neprilysin inhibitor–angiotensin II receptor blocker combination therapy (sacubitril/valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E-deficient Mice. Sci Rep 9(1):1–7

Suematsu Y, Ideishi A, Tashiro K, Miura SI (2021) Angiotensin receptor-neprilysin inhibitor suppressed cardiac dysfunction by angiogenesis in mice model of atherosclerosis. J Hypertens 1(39):e191

doi: 10.1097/01.hjh.0000746572.65667.fd

Chua SK, Lai WT, Chen LC, Hung HF (2021) The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials. J Clin Med 10(13):2824

pubmed: 34206864 pmcid: 8268164 doi: 10.3390/jcm10132824

Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, Apple FS, Burnett JC, Iyer S, Januzzi JL (2019) Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol 73(11):1273–1284

pubmed: 30898202 doi: 10.1016/j.jacc.2018.12.063

Vodovar N, Seronde MF, Laribi S, GREAT Network et al (2015) Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail 3(8):629–636

pubmed: 26251090 doi: 10.1016/j.jchf.2015.03.011

Cleland JG, Swedberg K (1998) Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The international ecadotril multi-centre dose-ranging study investigators. Lancet 351(9116):1657–1658

pubmed: 9620738 doi: 10.1016/S0140-6736(05)77712-6

Cleland JG, Swedberg K (1998) Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The Lancet 351(9116):1657–1658

doi: 10.1016/S0140-6736(05)77712-6

Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP, Solomon SD (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 17(5):510–517

pubmed: 25657064 doi: 10.1002/ejhf.232

Judge P, Haynes R, Landray MJ, Baigent C (2015) Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant 30(5):738–743

pubmed: 25140014 doi: 10.1093/ndt/gfu269

Lillyblad MP (2015) Dual angiotensin receptor and neprilysin inhibition with sacubitril/valsartan in chronic systolic heart failure: understanding the new PARADIGM. Ann Pharmacother 49(11):1237–1251

pubmed: 26175499 doi: 10.1177/1060028015593093

Chen Y, He Q, Mo DC, Chen L, Lu JL, Li RX, Huang J (2022) The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: a meta-analysis of randomized controlled trials. Medicine 101(41):e30904

pubmed: 36254034 pmcid: 9575833 doi: 10.1097/MD.0000000000030904

Shi V, Senni M, Streefkerk H, Modgill V, Zhou W, Kaplan A (2018) Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. Int J Cardiol 1(264):118–123

doi: 10.1016/j.ijcard.2018.03.121

Menendez JT (2016) The mechanism of action of LCZ696. Card Fail Rev 2(1):40

pubmed: 28785451 pmcid: 5491035 doi: 10.15420/cfr.2016:1:1

Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor—neprilysin inhibitor (ARNi). J Clin Pharmacol 50(4):401–414

pubmed: 19934029 doi: 10.1177/0091270009343932

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1):54–61

pubmed: 25403646 doi: 10.1161/CIRCULATIONAHA.114.013748

Langenickel TH, Dole WP (2012) Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today 9(4):e131–e139

Kobalava ZD, Pavlikova EP, Averkov OA, Merai I, Babaeva LA, Amirbegishvili IA, Kotovskaya YV, Moiseev VS (2015) First Experience of clinical application of LCZ696 an AT1-angiotensin receptors and neprilysin inhibitor in patients with chronic heart failure and reduced ejection fraction. Kardiologiia 55(7):14–25

pubmed: 26688921 doi: 10.18565/cardio.2015.7.14-25

Sutanto H, Dobrev D, Heijman J (2021) Angiotensin receptor-neprilysin inhibitor (ARNI) and cardiac arrhythmias. Int J Mol Sci 22(16):8994

pubmed: 34445698 pmcid: 8396594 doi: 10.3390/ijms22168994

Nikolic M, Srejovic I, Jovic J, Sretenovic J, Jeremic J, Cekerevac I, Simovic S, Djokovic D, Muric N, Stojic V, Bolevich SS. (2022) Sacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance. Reviews in Cardiovascular Medicine.

Valentim Goncalves A, Pereira-da-Silva T, Galrinho A, Rio P, Moura Branco L, Soares R, Ilhao Moreira R et al (2020) C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients. Am J Cardiovasc Dis 10:174–181

pubmed: 32923098 pmcid: 7486532

Ge Q, Zhao L, Ren XM, Ye P, Hu ZY (2019) LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis. Expe Biol Med 244:1028–1039

doi: 10.1177/1535370219861283

Butts B, Gary RA, Dunbar SB, Butler J (2015) The importance of NLRP3 inflammasome in heart failure. J Card Fail 21:586–593

pubmed: 25982825 pmcid: 4516025 doi: 10.1016/j.cardfail.2015.04.014

Okada M, Matsuzawa A, Yoshimura A, Ichijo H (2014) The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem 289:32926–32936

pubmed: 25288801 pmcid: 4239639 doi: 10.1074/jbc.M114.579961

Li X, Zhu Q, Wang Q, Zhang Q, Zheng Y, Wang L et al (2020) Protection of Sacubitril/Valsartan against pathological cardiac remodeling by inhibiting the NLRP3 inflammasome after relief of pressure overload in mice. Cardiovasc Drugs Ther 34:629–640

pubmed: 32444995 pmcid: 7497317 doi: 10.1007/s10557-020-06995-x

Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G (2012) Atherosclerosis as an inflammatory disease. Curr Pharm Des 18(28):4266–4288

pubmed: 22390643 doi: 10.2174/138161212802481237

Ou HC, Chou WC, Hung CH, Chu PM, Hsieh PL, Chan SH, Tsai KL (2019) Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway. Environ Toxicol 34(7):825–835

pubmed: 30963716 doi: 10.1002/tox.22750

Wu G, Zhu Q, Zeng J, Gu X, Miao Y, Xu W, Lv T, Song Y (2019) Extracellular mitochondrial DNA promote NLRP3 inflammasome activation and induce acute lung injury through TLR9 and NF-κB. J Thorac Dis 11(11):4816

pubmed: 31903272 pmcid: 6940233 doi: 10.21037/jtd.2019.10.26

Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R, Polykratis A, Kollias G, de Winther MP, Pasparakis M (2008) Endothelial cell-specific NF-κB inhibition protects mice from atherosclerosis. Cell Metab 8(5):372–383

pubmed: 19046569 doi: 10.1016/j.cmet.2008.08.016

Mallavia B, Recio C, Oguiza A, Ortiz-Muñoz G, Lazaro I, Lopez-Parra V, Lopez-Franco O, Schindler S, Depping R, Egido J, Gomez-Guerrero C (2013) Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis. Am J Pathol 182(5):1910–1921

pubmed: 23597852 doi: 10.1016/j.ajpath.2013.01.022

Fujiwara N, Kobayashi K (2005) Macrophages in inflammation. Current Drug Targets-Inflamm Allergy 4(3):281–286

doi: 10.2174/1568010054022024

Tabata T, Mine S, Kawahara C, Okada Y, Tanaka Y (2003) Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. Biochem Biophys Res Commun 305(2):380–385

pubmed: 12745086 doi: 10.1016/S0006-291X(03)00771-X

Akhter N, Wilson A, Thomas R, Al-Rashed F, Kochumon S, Al-Roub A, Arefanian H, Al-Madhoun A, Al-Mulla F, Ahmad R, Sindhu S (2021) Ros/tnf-α crosstalk triggers the expression of il-8 and mcp-1 in human monocytic thp-1 cells via the nf-κb and erk1/2 mediated signaling. Int J Mol Sci 22(19):10519

pubmed: 34638857 pmcid: 8508672 doi: 10.3390/ijms221910519

Abedimanesh N, Motlagh B, Abedimanesh S, Bathaie SZ, Separham A, Ostadrahimi A (2020) Effects of crocin and saffron aqueous extract on gene expression of SIRT1, AMPK, LOX1, NF-κB, and MCP-1 in patients with coronary artery disease: a randomized placebo-controlled clinical trial. Phytother Res 34(5):1114–1122

pubmed: 31797473 doi: 10.1002/ptr.6580

Hoseini Z, Sepahvand F, Rashidi B, Sahebkar A, Masoudifar A, Mirzaei H (2018) NLRP3 inflammasome: Its regulation and involvement in atherosclerosis. J Cell Physiol 233(3):2116–2132

pubmed: 28345767 doi: 10.1002/jcp.25930

Djurić T, Stanković A, Končar I, Radak D, Davidović L, Alavantić D, Živković M (2011) Association of MMP-8 promoter gene polymorphisms with carotid atherosclerosis: preliminary study. Atherosclerosis 219(2):673–678

pubmed: 21906737 doi: 10.1016/j.atherosclerosis.2011.08.025

Basurto L, Gregory MA, Hernández SB, Sánchez-Huerta L, Martínez AD, Manuel-Apolinar L, Avelar FJ, Alonso LA, Sánchez-Arenas R (2019) Monocyte chemoattractant protein-1 (MCP-1) and fibroblast growth factor-21 (FGF-21) as biomarkers of subclinical atherosclerosis in women. Exp Gerontol 1(124):110624

doi: 10.1016/j.exger.2019.05.013

Jacinto TA, Meireles GS, Dias AT, Aires R, Porto ML, Gava AL, Vasquez EC, Pereira TM, Campagnaro BP, Meyrelles SS (2018) Increased ROS production and DNA damage in monocytes are biomarkers of aging and atherosclerosis. Biol Res 51(1):1–3

doi: 10.1186/s40659-018-0182-7

Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ (2018) Concept and connotation of oxidative stress in preeclampsia. J Lab Physicians 10(03):276–282

pubmed: 30078962 pmcid: 6052821 doi: 10.4103/JLP.JLP_26_18

Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD (2019) Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxid Med Cell Longev. https://doi.org/10.1155/2019/8563845

doi: 10.1155/2019/8563845 pubmed: 31354915 pmcid: 6636482

Al-Kuraishy HM, Al-Gareeb AI, Al-Hussaniy HA, Al-Harcan NA, Alexiou A, Batiha GE (2022) Neutrophil Extracellular Traps (NETs) and Covid-19: a new frontiers for therapeutic modality. Int Immunopharmacol 6:108516

doi: 10.1016/j.intimp.2021.108516

Poznyak AV, Grechko AV, Orekhova VA, Khotina V, Ivanova EA, Orekhov AN (2020) NADPH oxidases and their role in atherosclerosis. Biomedicines 8(7):206

pubmed: 32664404 pmcid: 7399834 doi: 10.3390/biomedicines8070206

Hussien NR, Al-Niemi MS, Al-Kuraishy HM, Al-Gareeb AI (2021) Statins and Covid-19: the neglected front of bidirectional effects. J Pak Med Assoc 71(Suppl 8):S133–S136

Manea SA, Vlad ML, Fenyo IM, Lazar AG, Raicu M, Muresian H, Simionescu M, Manea A (2020) Pharmacological inhibition of histone deacetylase reduces NADPH oxidase expression, oxidative stress and the progression of atherosclerotic lesions in hypercholesterolemic apolipoprotein E-deficient mice; potential implications for human atherosclerosis. Redox Biol 1(28):101338

doi: 10.1016/j.redox.2019.101338

Lixia G, Haiyun Z, Xia Z (2021) The clinical effects of resveratrol on atherosclerosis treatment and its effect on the expression of NADPH oxidase complex genes in vascular smooth muscle cell line. Cell Mol Biol (Noisy-le-grand) 67(3):148–152

pubmed: 34933718 doi: 10.14715/cmb/2021.67.3.22

Zhang Y, Murugesan P, Huang K, Cai H (2020) NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets. Nat Rev Cardiol 17(3):170–194

pubmed: 31591535 doi: 10.1038/s41569-019-0260-8

Al-Thomali AW, Al-Kuraishy HM, Al-Gareeb AI, K. Al-buhadiliy A, De Waard M, Sabatier JM, Khan Khalil AA, Saad HM, Batiha GE. (2022) Role of neuropilin 1 in COVID-19 patients with acute ischemic stroke. Biomedicines. 10(8):2032

Sun Y, Lu Y, Saredy J, Wang X, Drummer C IV, Shao Y, Saaoud F, Xu K, Liu M, Yang WY, Jiang X (2020) ROS systems are a new integrated network for sensing homeostasis and alarming stresses in organelle metabolic processes. Redox Biol 1(37):101696

doi: 10.1016/j.redox.2020.101696

Imran M, Hassan MQ, Akhtar MS, Rahman O, Akhtar M, Najmi AK (2019) Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats. Clin Exp Hypertens 41(1):62–69

pubmed: 29595329 doi: 10.1080/10641963.2018.1441862

Croteau D, Qin F, Chambers JM, Kallick E, Luptak I, Panagia M, Pimentel DR, Siwik DA, Colucci WS (2020) Differential effects of sacubitril/valsartan on diastolic function in mice with obesity-related metabolic heart disease. Basic Transl Sci 5(9):916–927

Nna VU, Abu Bakar AB, Ahmad A, Eleazu CO, Mohamed M (2019) Oxidative stress, NF-κb-mediated inflammation and apoptosis in the testes of streptozotocin–induced diabetic rats: combined protective effects of malaysian propolis and metformin. Antioxidants 8(10):465

pubmed: 31600920 pmcid: 6826571 doi: 10.3390/antiox8100465

Wang X, Bai M (2021) CircTM7SF3 contributes to oxidized low-density lipoprotein-induced apoptosis, inflammation and oxidative stress through targeting miR-206/ASPH axis in atherosclerosis cell model in vitro. BMC Cardiovasc Disord 21(1):1–4

Peng S, Lu XF, Qi YD, Li J, Xu J, Yuan TY, Wu XY, Ding Y, Li WH, Zhou GQ, Wei Y (2020) LCZ696 ameliorates oxidative stress and pressure overload-induced pathological cardiac remodeling by regulating the Sirt3/MnSOD pathway. Oxid Med Cell Longev. https://doi.org/10.1155/2020/9815039

doi: 10.1155/2020/9815039 pubmed: 33343808 pmcid: 7732383

Trivedi RK, Polhemus DJ, Li Z, Yoo D, Koiwaya H, Scarborough A, Goodchild TT, Lefer DJ (2018) Combined angiotensin receptor–neprilysin inhibitors improve cardiac and vascular function via increased no bioavailability in heart failure. J Am Heart Assoc 7(5):e008268

pubmed: 29502102 pmcid: 5866338 doi: 10.1161/JAHA.117.008268

Schulz E, Gori T, Münzel T (2011) Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 34(6):665–673

pubmed: 21512515 doi: 10.1038/hr.2011.39

Seki T, Goto K, Kansui Y, Ohtsubo T, Matsumura K, Kitazono T (2017) Angiotensin II receptor–neprilysin inhibitor sacubitril/valsartan improves endothelial dysfunction in spontaneously hypertensive rats. J Am Heart Assoc 6(10):e006617

pubmed: 29042424 pmcid: 5721864 doi: 10.1161/JAHA.117.006617

Gao A, Wang Y, Gao X, Tian W (2021) LCZ696 ameliorates lipopolysaccharide-induced endothelial injury. Aging (Albany NY) 13(7):9582

pubmed: 33839697 doi: 10.18632/aging.202692

Kockx MM, Herman AG (2000) Apoptosis in atherosclerosis: beneficial or detrimental. Cardiovasc Res 45(3):736–746

pubmed: 10728396 doi: 10.1016/S0008-6363(99)00235-7

Shan R et al (2021) Apoptosis, autophagy and atherosclerosis: relationships and the role of Hsp27. Pharmacol Res 166:105169

pubmed: 33053445 doi: 10.1016/j.phrs.2020.105169

Paone S et al (2019) Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis. Cell Mol Life Sci 76(6):1093–1106

pubmed: 30569278 doi: 10.1007/s00018-018-2983-9

Kim Nam-Ho, Kang Peter M (2010) Apoptosis in cardiovascular diseases: mechanism and clinical implications. Korean Circ J 40(7):299–305

pubmed: 20664736 pmcid: 2910284 doi: 10.4070/kcj.2010.40.7.299

Xia Y et al (2017) LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol 108:138–148

pubmed: 28623750 doi: 10.1016/j.yjmcc.2017.06.003

Moore KJ, Sheedy FJ, Fisher EA (2013) Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 13(10):709–721

pubmed: 23995626 pmcid: 4357520 doi: 10.1038/nri3520

Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, Yuan Q, Yu H, Xu W, Xie X (2019) New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol 1(20):247–260

doi: 10.1016/j.redox.2018.09.025

Suzuki K et al (2021) Pulse pressure, prognosis, and influence of sacubitril/valsartan in heart failure with preserved ejection fraction. Hypertension 77(2):546–556

pubmed: 33356401 doi: 10.1161/HYPERTENSIONAHA.120.16277

Packer Milton (2018) Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure. Eur J Heart Fail 20(6):973–977

pubmed: 29603541 doi: 10.1002/ejhf.1185

García RD, Ramirez JM, Peral de Bruno M, Miatello RM, Renna NF. Dual ARB/NEP Inhibition with LCZ696 improved endothelial regeneration in an experimental model of metabolic syndrome.

Al-Kuraishy HM, Hussien NR, Al-Naimi MS, Al-Buhadily AK, Al-Gareeb AI, Lungnier C (2020) Renin-Angiotensin system and fibrinolytic pathway in COVID-19: one-way skepticism. Biomed Biotechnol Res J (BBRJ) 4(5):33

Lugnier C, Al-Kuraishy HM, Rousseau E (2021) PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking. Biochem Pharmacol 1(185):114431

doi: 10.1016/j.bcp.2021.114431

Al-Kuraishy HM, Al-Gareeb AI, Al-Nami MS (2020) Irbesartan attenuates gentamicin-induced nephrotoxicity in rats through modulation of oxidative stress and endogenous antioxidant capacity. Int J Prevent Med 11(3):200–205

Grote K, Drexler H, Schieffer B (2004) Renin–angiotensin system and atherosclerosis. Nephrol Dial Transplant 19(4):770–773

pubmed: 15031327 doi: 10.1093/ndt/gfh030

Schmidt-Ott KM, Kagiyama S, Phillips MI (2000) The multiple actions of angiotensin II in atherosclerosis. Regul Pept 93(1–3):65–77

pubmed: 11033054 doi: 10.1016/S0167-0115(00)00178-6

Liu X, Gao RW, Li M, Si CF, He YP, Wang M, Yang Y, Zheng QY, Wang CY (2016) The ROS derived mitochondrial respirstion not from NADPH oxidase plays key role in Celastrol against angiotensin II-mediated HepG2 cell proliferation. Apoptosis 21(11):1315–1326

pubmed: 27658784 doi: 10.1007/s10495-016-1294-6

Jansen T, Kröller-Schön S, Schönfelder T, Foretz M, Viollet B, Daiber A, Oelze M, Brandt M, Steven S, Kvandová M, Kalinovic S (2018) α1AMPK deletion in myelomonocytic cells induces a pro-inflammatory phenotype and enhances angiotensin II-induced vascular dysfunction. Cardiovasc Res 114(14):1883–1893

pubmed: 29982418 pmcid: 6455900 doi: 10.1093/cvr/cvy172

Husain K, Hernandez W, Ansari RA, Ferder L (2015) Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem 6(3):209

pubmed: 26322175 pmcid: 4549761 doi: 10.4331/wjbc.v6.i3.209

Wu Y, Liu Y, Zhang L, Wen L, Xie Y (2022) Aconiti lateralis radix praeparata total alkaloids exert anti-RA effects by regulating NF-κB and JAK/STAT signaling pathways and promoting apoptosis. Front Pharmacol 1:13

Ohishi M, Dusting GJ, Fennessy PA, Mendelsohn FA, Li XC, Zhuo JL (2010) Increased expression and co-localization of ACE, angiotensin II AT1 receptors and inducible nitric oxide synthase in atherosclerotic human coronary arteries. Int J Physiol Pathophysiol Pharmacol 2(2):111

pubmed: 21179388 pmcid: 3004229

Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y (2020) Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: association with improvement of fibrinolysis. J Diabetes Complications 34(11):107703

pubmed: 32883567 doi: 10.1016/j.jdiacomp.2020.107703

valsartan are more effective than ACEIs through attenuation of alternative production of AngII and activation of vasculoprotective AT2R

Poznyak AV, Bharadwaj D, Prasad G, Grechko AV, Sazonova MA, Orekhov AN (2021) Renin-angiotensin system in pathogenesis of atherosclerosis and treatment of CVD. Int J Mol Sci 22(13):6702

pubmed: 34206708 pmcid: 8269397 doi: 10.3390/ijms22136702

Lévy BI, Mourad JJ (2022) Renin angiotensin blockers and cardiac protection: from basis to clinical trials. Am J Hypertens 35(4):293–302

pubmed: 34265036 doi: 10.1093/ajh/hpab108

Ding Y, Chen J, Cui G, Wei Y, Lu C, Wang L, Diao H (2016) Pathophysiological role of osteopontin and angiotensin II in atherosclerosis. Biochem Biophys Res Commun 471(1):5–9

pubmed: 26828266 doi: 10.1016/j.bbrc.2016.01.142

Wolak T (2014) Osteopontin–a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis 236(2):327–337

pubmed: 25128758 doi: 10.1016/j.atherosclerosis.2014.07.004

Ding Z, Liu S, Wang X, Khaidakov M, Dai Y, Deng X, Fan Y, Xiang D, Mehta JL (2015) Lectin-like ox-LDL receptor-1 (LOX-1)–Toll-like receptor 4 (TLR4) interaction and autophagy in CATH a differentiated cells exposed to angiotensin II. Mol Neurobiol 51(2):623–32

pubmed: 24902807 doi: 10.1007/s12035-014-8756-z

Kattoor AJ, Kanuri SH, Mehta JL (2019) Role of Ox-LDL and LOX-1 in atherogenesis. Curr Med Chem 26(9):1693–1700

pubmed: 29737246 doi: 10.2174/0929867325666180508100950

Aoyama T, Minatoguchi S (2011) The effect of ARB on prevention of atherosclerosis. Nihon rinsho Jpn J Clin Med 69(1):92–9

Husain K, Suarez E, Isidro A, Ferder L (2010) Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 32(4):296–304

pubmed: 20720404 doi: 10.1159/000319445

Da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, Vergona R, Sullivan ME, Wang YX (2005) Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 178(1):9–17

pubmed: 15585195 doi: 10.1016/j.atherosclerosis.2004.08.023

Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Hirose E, Kobayashi Y, Ohkawa K, Ohara M (2012) Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis 220(1):134–138

pubmed: 22119063 doi: 10.1016/j.atherosclerosis.2011.10.013

Katogiannis K, Ikonomidis I, Stamouli M, Makavos G, Tsilivarakis D, Koliou G, Vythoulkas D, Tsirigotis P (2021) Effect of sacubitril/valsartan on left ventricular longitudinal strain in patients with hematologic malignancies after bone marrow transplantation. Eur Heart J 42(Supplement_1):ehab724-020

doi: 10.1093/eurheartj/ehab724.020

Wei S, Sun J, Li Y, Xu K, Wang M, Zhang Y (2022) Losartan attenuates atherosclerosis in uremic mice by regulating Treg/Th17 balance via mediating PTEN/PI3K/Akt pathway. Nephron 17:1–1

Sansoè G, Aragno M, Wong F (2020) Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. Liver Int 40(1):18–31

pubmed: 31580514 doi: 10.1111/liv.14272

Anguiano L, Riera M, Pascual J, Soler MJ (2017) Circulating ACE2 in cardiovascular and kidney diseases. Curr Med Chem 24(30):3231–3241

pubmed: 28413960 doi: 10.2174/0929867324666170414162841

Wang Y, Tikellis C, Thomas MC, Golledge J (2013) Angiotensin converting enzyme 2 and atherosclerosis. Atherosclerosis 226(1):3–8

pubmed: 22947420 doi: 10.1016/j.atherosclerosis.2012.08.018

Bossi F, Bernardi S, De Nardo D, Bramante A, Candido R, Carretta R, Fischetti F, Fabris B (2016) Angiotensin 1–7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitro. Atherosclerosis 1(244):121–130

doi: 10.1016/j.atherosclerosis.2015.11.017

AlAnazi FH, Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Ogaly HA, Alanazi YA, Saad HM, Batiha GE (2019) Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: controversial points and a promising arena. J Diabetes. https://doi.org/10.1111/1753-0407.13389

doi: 10.1111/1753-0407.13389

Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, Moradi H (2018) LCZ696 (sacubitril/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease. J Cardiac Fail 24(4):266–275

doi: 10.1016/j.cardfail.2017.12.010

Renna NF, Ramirez JM, Garcia RD, Miatello RM. (2018) Role of Insulin Resistance in Vascular Inflammation. InUltimate Guide to Insulin . IntechOpen

Jordan J, Stinkens R, Jax T, Engeli S, Blaak EE, May M, Havekes B, Schindler C, Albrecht D, Pal P, Heise T (2017) Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther 101(2):254–263

pubmed: 27542885 doi: 10.1002/cpt.455

Di Pino A, DeFronzo RA (2019) Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. Endocr Rev 40(6):1447–1467

pubmed: 31050706 pmcid: 7445419 doi: 10.1210/er.2018-00141

Kurata M, Okura T, Irita J, Enomoto D, Nagao T, Jotoku M, Miyoshi K, Desilva VR, Higaki J (2011) Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. J Hum Hypertens 25(5):334–339

pubmed: 20664555 doi: 10.1038/jhh.2010.73

Song C, Hongbing Y, Shujuan C, Shuzheng L, Yundai C, Guoxiang H, Xiantao S, Zening J, Lijun M, CuiSong V (2011) The impact of Valsartan on vascular endothelial cells in plaque with ApoE knockout mice. Heart 97(Suppl 3):A23–A24

doi: 10.1136/heartjnl-2011-300867.66

Martyniak A, Tomasik PJ (2023) A New perspective on the renin-angiotensin system. Diagnostics 13(1):16

doi: 10.3390/diagnostics13010016

Mori J, Zhang L, Oudit GY, Lopaschuk GD (2013) Impact of the renin–angiotensin system on cardiac energy metabolism in heart failure. J Mol Cell Cardiol 1(63):98–106

doi: 10.1016/j.yjmcc.2013.07.010

Kusaka H et al (2015) LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone. Am J Hypertens 28:1409–1417

pubmed: 25762811 doi: 10.1093/ajh/hpv015

Gupta DK, Daniels LB, Cheng S, deFilippi CR, Criqui MH, Maisel AS, Lima JA, Bahrami H, Greenland P, Cushman M, Tracy R (2017) Differences in natriuretic peptide levels by race/ethnicity (from the multi-ethnic study of atherosclerosis). Am J Cardiol 120(6):1008–1015

pubmed: 28750825 pmcid: 5575954 doi: 10.1016/j.amjcard.2017.06.030

Imanishi T et al (2008) Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. Hypertens Res 31:575–584

pubmed: 18497479 doi: 10.1291/hypres.31.575

McMurray JJ et al (2014) Angiotensin- neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

pubmed: 25176015 doi: 10.1056/NEJMoa1409077

Hayashi K, Sasamura H, Azegami T, Itoh H (2012) Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan. J Atheroscler Thromb 19:736–746

pubmed: 22576470

Solomon SD et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. Lancet 380:1387–1395

pubmed: 22932717 doi: 10.1016/S0140-6736(12)61227-6

Mogensen UM et al (2017) The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J 188:35–41

pubmed: 28577679 doi: 10.1016/j.ahj.2017.02.034

Quagliariello V, Buccolo S, Iovine M, Maurea F, Rea D, Barbieri A, Maurea N (2021) 54 Sacubitril–valsartan (LCZ 696) improves longitudinal strain and ejection fraction in preclinical models treated with doxorubicin through NLRP3, MyD88, and pro-fibrotic chemokines. Eur Heart J Suppl 23(Supplement_G):suab130-008

doi: 10.1093/eurheartj/suab130.008

Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T (2006) Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 117(4):385–392

pubmed: 15896827 doi: 10.1016/j.thromres.2005.04.008

Li QZ, Deng Q, Li JQ, Yi GH, Zhao SP (2005) Valsartan reduces interleukin-1β secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clin Chim Acta 355(1–2):131–136

pubmed: 15820487 doi: 10.1016/j.cccn.2004.12.006

Yandrapalli S, Aronow WS, Mondal P, Chabbott DR (2017) Limitations of sacubitril/valsartan in the management of heart failure. Am J Ther 24(2):e234–e239

pubmed: 27574931 doi: 10.1097/MJT.0000000000000473

Sorrentino A, Steinhorn B, Troncone L (2019) Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress. Am J Physiol Heart Circ Physiol 317:H617–H626

pubmed: 31298558 pmcid: 6766720 doi: 10.1152/ajpheart.00177.2019

D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M (2017) Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 19:710–717

pubmed: 28326642 doi: 10.1002/ejhf.799

Cangiano E, Marchesini J, Campo G, Francolini G, Fortini C, Carrà G, Miccoli M, Ceconi C, Tavazzi L, Ferrari R (2011) ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am J Cardiovasc Drugs 11:189–198

pubmed: 21619382 doi: 10.2165/11589400-000000000-00000

Wang ZC, Qi J, Liu LM, Li J, Xu HY, Liang B, Li B (2017) Valsartan reduces AT1-AA-induced apoptosis through suppression oxidative stress mediated ER stress in endothelial progenitor cells. Eur Rev Med Pharmacol Sci 21(5):1159–1168

pubmed: 28338173

Madan N, Lee AK, Matsushita K, Hoogeveen RC, Ballantyne CM, Selvin E, McEvoy JW (2019) Relation of isolated systolic hypertension and pulse pressure to high-sensitivity cardiac troponin-T and N-terminal pro-B-type natriuretic peptide in older adults (from the atherosclerosis risk in communities study). Am J Cardiol 124(2):245–252

pubmed: 31088661 pmcid: 6581585 doi: 10.1016/j.amjcard.2019.04.030

Liu J, Lin Q, Guo D, Yang Y, Zhang X, Tu J, Ning X, Song Y, Wang J (2020) Association between pulse pressure and carotid intima-media thickness among low-income adults aged 45 years and older: a population-based cross-sectional study in rural China. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2020.547365

doi: 10.3389/fcvm.2020.547365 pubmed: 33796567 pmcid: 7786017

Zheng L, Xia B, Zhang X, Zhao Y (2021) A meta-analysis on the effect and safety of LCZ696 in the treatment of hypertension. Cardiol Res Pract. https://doi.org/10.1155/2021/8867578

doi: 10.1155/2021/8867578 pubmed: 34426769 pmcid: 8380156

Alsaidan AA, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Alsayed KA, Saad HM, Batiha GE (2023) The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread. Immun Inflamm Dis 11(3):e798

pubmed: 36988260 pmcid: 10022425 doi: 10.1002/iid3.798

Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE (2023) The potential therapeutic effect of statins in multiple sclerosis: beneficial or detrimental effects. Inflammopharmacology 9:1–2

Sami OM, Shams HA, Aziz HM, Al-kuraishy HM (2022) The Substantial effects of statins therapy on PCSK9 and adipocytokine in dyslipidemic non-diabetic patients: prevailing motive. HIV Nursing 22(2):1434–1439

Alomair BM, Al-Kuraishy HM, Al-Gareeb AI, Al-Hamash SM, De Waard M, Sabatier JM, Saad HM, El-Saber BG (2022) Montelukast and acute coronary syndrome: the endowed drug. Pharmaceuticals 15(9):1147

pubmed: 36145367 pmcid: 9500901 doi: 10.3390/ph15091147

Alkhayyat SS, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, AboKamer AM, Batiha GE, Simal-Gandara J (2022) Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail. Inflamm Res 8:1–9

Al-Kuraishy HM, Al-Gareeb AI, Negm WA, Alexiou A, Batiha GE (2022) Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective. Inflammopharmacology 30(5):1493–1501

pubmed: 35922738 pmcid: 9362167 doi: 10.1007/s10787-022-01038-3

Batiha GE, Al-Gareeb AI, Rotimi D, Adeyemi OS, Al-Kuraishy HM (2022) Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer. Scientific African 22:e01407

doi: 10.1016/j.sciaf.2022.e01407

Alrouji M, Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Jabir MS, Saad HM, Batiha GE (2023) NF-κB/NLRP3 inflammasome axis and risk of Parkinson’s disease in Type 2 diabetes mellitus: a narrative review and new perspective. J Cell Mol Med 27(13):1775–1789

pubmed: 37210624 pmcid: 10315781 doi: 10.1111/jcmm.17784

Batiha GE, Al-Gareeb AI, Elekhnawy E, Al-Kuraishy HM (2022) Potential role of lipoxin in the management of COVID-19: a narrative review. Inflammopharmacology 30(6):1993–2001

pubmed: 36114383 pmcid: 9483298 doi: 10.1007/s10787-022-01070-3

Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE (2022) COVID-19 and L-arginine supplementations: yet to find the missed key. Curr Protein Pept Sci 23(3):166–169

pubmed: 35549865 doi: 10.2174/1389203723666220512104039

Al-Kuraishy HM, Al-Gareeb AI, Fageyinbo MS, Batiha GE (2022) Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19. Future Sci OA 8(5):FSO797

pubmed: 35662743 pmcid: 9017700 doi: 10.2144/fsoa-2021-0099

Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Ashour NA, Negm WA (2023) Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach. Inflammopharmacology 19:1–1

doi: 10.1007/s10787-022-01087-8

Babalghith AO, Al-Kuraishy HM, Al-Gareeb AI, De Waard M, Al-Hamash SM, Jean-Marc S, Negm WA, Batiha GE (2022) The role of berberine in Covid-19: potential adjunct therapy. Inflammopharmacology 30(6):2003–2016

pubmed: 36183284 pmcid: 9526677 doi: 10.1007/s10787-022-01080-1

Alorabi M, Cavalu S, Al-Kuraishy HM, Al-Gareeb AI, Mostafa-Hedeab G, Negm WA, Youssef A, El-Kadem AH, Saad HM, Batiha GE (2022) Pentoxifylline and berberine mitigate diclofenac-induced acute nephrotoxicity in male rats via modulation of inflammation and oxidative stress. Biomed Pharmacother 1(152):113225

doi: 10.1016/j.biopha.2022.113225

Rasheed HA, Al-Naimi MS, Hussien NR, Al-Harchan NA, Al-Kuraishy HM, Al-Gareeb AI (2020) New insight into the effect of lycopene on the oxidative stress in acute kidney injury. Int J Crit Illn Inj Sci 10(Suppl 1):11

pubmed: 33376684 pmcid: 7759068

Al-Kuraishy HM, Al-Gareeb AI, Al-Nami MS (2019) Vinpocetine improves oxidative stress and pro-inflammatory mediators in acute kidney injury. Int J Prev Med 10(1):142

pubmed: 31516683 pmcid: 6710925 doi: 10.4103/ijpvm.IJPVM_5_19

Abdul-Hadi MH, Naji MT, Shams HA, Sami OM, Al-Harchan NA, Al-Kuraishy HM, Al-Gareeb AI (2020) Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: the potential role of metformin and sitagliptin. Biomed Biotechnol Res J (BBRJ) 4(2):166

Al-Kuraishy HM, Al-Gareeb AI, Alzahrani KJ, Cruz-Martins N, Batiha GE (2021) The potential role of neopterin in Covid-19: a new perspective. Mol Cell Biochem 476:4161–4166

pubmed: 34319496 pmcid: 8317144 doi: 10.1007/s11010-021-04232-z

Kadhim SS, Al-Windy SA, Al-Kuraishy HM, Al-Gareeb AI (2019) Endothelin-1 is a surrogate biomarker link severe periodontitis and endothelial dysfunction in hypertensive patients: the potential nexus. J Int Oral Health 11(6):369

doi: 10.4103/jioh.jioh_158_19

Al-kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Batiha GE (2022) Ginkgo biloba in the management of the COVID-19 severity. Arch Pharm 355(10):2200188

doi: 10.1002/ardp.202200188

Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ, Alexiou A, Mukerjee N, Batiha GE (2022) An insight into the placental growth factor (PlGf)/angii axis in Covid-19: a detrimental intersection. Biotechnol Genet Eng Rev 15:1–20

Al-Kuraishy HM, Batiha GE, Faidah H, Al-Gareeb AI, Saad HM, Simal-Gandara J (2022) Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology 31:1

pubmed: 36418600 pmcid: 9685016

Saad HM, Tourky GF, Al-Kuraishy HM, Al-Gareeb AI, Khattab AM, Elmasry SA, Alsayegh AA, Hakami ZH, Alsulimani A, Sabatier JM, Eid MW (2022) The potential role of MUC16 (CA125) biomarker in lung cancer: a magic biomarker but with adversity. Diagnostics 12(12):2985

pubmed: 36552994 pmcid: 9777200 doi: 10.3390/diagnostics12122985

Batiha GE, Al-Kuraishy HM, Al-Maiahy TJ, Al-Buhadily AK, Saad HM, Al-Gareeb AI, Simal-Gandara J (2022) Plasminogen activator inhibitor 1 and gestational diabetes: the causal relationship. Diabetol Metab Syndr 14(1):1–6

doi: 10.1186/s13098-022-00900-2

Al-Kuraishy HM, Al-Gareeb AI, Al-Harcan NA, Alexiou A, Batiha GE (2023) Tranexamic acid and plasminogen/plasmin glaring paradox in COVID-19. Endocr Metab Immune Disord Drug Targets 23(1):35–45

pubmed: 35927893 doi: 10.2174/1871530322666220801102402

Possible role of LCZ696 in atherosclerosis: new inroads and perspective.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Hayder M Al-Kuraishy (HM)

Ali I Al-Gareeb (AI)

Engy Elekhnawy (E)

Gaber El-Saber Batiha (GE)

Classifications MeSH